{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:07Z","timestamp":1793155747651,"version":"4.5.0"},"reference-count":115,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["DJCLS 13 R\/2021"],"award-info":[{"award-number":["DJCLS 13 R\/2021"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple myeloma (MM) is a type of hematologic cancer characterized by the uncontrolled clonal expansion of plasma cells in the bone marrow (BM). This leads to significant dysfunction and suppression of the immune system in affected patients. Myeloma cells employ sophisticated strategies to manipulate immune and non-immune cells, evading immune surveillance and enhancing their survival. One key factor in this evasion is the disruption of dendritic cell (DC)-mediated immune mechanisms. Extensive evidence indicates that in the presence of myeloma cells, DC numbers are notably reduced, and their phenotype and function are altered, impairing their ability to present antigens and activate robust T-cell responses effectively. Despite rapid advances in MM treatment, with promising strategies such as DC-based vaccines being already achieved, DC dysfunction remains a substantial hurdle, associated with or contributing to poor therapeutic outcomes, disease relapse, and MM\u2019s persistence as an incurable disease. To address these challenges, it is essential to understand the intricate mechanisms through which myeloma cells transform DCs into their \u201caccomplices,\u201d undermining immune responses. This review comprehensively summarizes the current understanding of the role of DCs in MM. Additionally, it evaluates the potential of DCs in anti-MM immunotherapy, discussing persistent challenges and highlighting emerging perspectives that may lead to promising breakthroughs for improved patient outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1575509","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T01:24:23Z","timestamp":1744853063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Dendritic cells in multiple myeloma: from immune evasion to therapeutic potential"],"prefix":"10.3389","volume":"16","author":[{"given":"Melanie Andrea","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Morschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Autenrieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa070389","article-title":"Clinical course and prognosis of smoldering (Asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v149.12","article-title":"Epidemiology, genetics and treatment of multiple myeloma and precursor diseases","volume":"149","author":"Hemminki","year":"2021","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1346211","article-title":"Different evasion strategies in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcdb.2018.04.015","article-title":"Human dendritic cells","volume":"86","author":"Collin","year":"2019","journal-title":"Semin Cell Dev Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401159","article-title":"Human CD141+ Dendritic cells induce CD4+ T cells to produce type 2 cytokines","volume":"193","author":"Yu","year":"2014","journal-title":"J Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111457","article-title":"Characterization of resident and migratory dendritic cells in human lymph nodes","volume":"209","author":"Segura","year":"2012","journal-title":"J Exp Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00971","article-title":"Human blood CD1c+ Dendritic cells promote th1 and th17 effector function in memory CD4+ T cells","volume":"8","author":"Rojas","year":"2017","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.immuni.2023.07.001","article-title":"Dendritic cell type 3 arises from Ly6C+ monocyte-dendritic cell progenitors","volume":"56","author":"Liu","year":"2023","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.immuni.2019.08.008","article-title":"Single-cell analysis of human mononuclear phagocytes reveals subset-defining markers and identifies circulating inflammatory dendritic cells","volume":"51","author":"Dutertre","year":"2019","journal-title":"Immunity"},{"key":"B13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.immuni.2018.12.027","article-title":"Plasmacytoid dendritic cells: Development, regulation, and function","volume":"50","author":"Reizis","year":"2019","journal-title":"Immunity"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-061020-053707","article-title":"Dendritic cells revisited","volume":"39","author":"Cabeza-Cabrerizo","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00726-4","article-title":"Dendritic cell migration in inflammation and immunity","volume":"18","author":"Liu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s11658-024-00602-9","article-title":"Dysregulated dendritic cells in sepsis: Functional impairment and regulated cell death","volume":"29","author":"Zheng","year":"2024","journal-title":"Cell Mol Biol Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-1804","article-title":"Cancer immunoediting in the era of immuno-oncology","volume":"28","author":"Gubin","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.03.60","article-title":"The evolving understanding of immunoediting and the clinical impact of immune escape","volume":"10","author":"McCoach","year":"2018","journal-title":"J Thorac Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature06309","article-title":"Adaptive immunity maintains occult cancer in an equilibrium state","volume":"450","author":"Koebel","year":"2007","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: Effects of chromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Curr Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/cancers12020323","article-title":"Ixazomib Improves Bone Remodeling and Counteracts sonic Hedgehog signaling Inhibition Mediated by Myeloma Cells","volume":"12","author":"Tibullo","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090977","article-title":"Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells","volume":"99","author":"Noll","year":"2014","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/cancers12040988","article-title":"Challenges for immunotherapy in multiple myeloma: Bone marrow microenvironment-mediated immune suppression and immune resistance","volume":"12","author":"Holthof","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: Friend or foe","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052136","article-title":"Enhancement of clonogenicity of human multiple myeloma by dendritic cells","volume":"203","author":"Kukreja","year":"2006","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213629","article-title":"Impaired function of dendritic cells within the tumor microenvironment","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12596","article-title":"Dysfunction of dendritic cells in tumor microenvironment and immunotherapy","volume":"44","author":"Chen","year":"2024","journal-title":"Cancer Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60644","article-title":"The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice","volume":"122","author":"Zelenay","year":"2012","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"Janco","year":"2015","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumor immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1365-2249.2006.03037.x","article-title":"Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma","volume":"144","author":"Brimnes","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2828","article-title":"Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes","volume":"102","author":"Hayashi","year":"2003","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1182\/blood-2018-99-117296","article-title":"APRIL is significantly elevated at all stages of multiple myeloma (MM) and interferes with anti-bcma monoclonal antibody-mediated cytolysis, supporting the clinical evaluation of bion-1301 as a novel therapeutic approach in MM","volume":"132","author":"Tai","year":"2018","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur J Hematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4512","article-title":"The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature","volume":"106","author":"Moreaux","year":"2005","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601746","article-title":"Human plasmacytoid dendritic cells display and shed B cell maturation antigen upon TLR engagement","volume":"198","author":"Schuh","year":"2017","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1852517","article-title":"Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma","volume":"2017","author":"Musolino","year":"2017","journal-title":"Mediators Inflam"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6491","DOI":"10.3390\/jcm11216491","article-title":"Pathways of angiogenic and inflammatory cytokines in multiple myeloma: Role in plasma cell clonal expansion and drug resistance","volume":"11","author":"Melaccio","year":"2022","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0327","article-title":"Dendritic cells and Malignant plasma cells: an alliance in multiple myeloma tumor progression","volume":"16","author":"Tucci","year":"2011","journal-title":"Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201343601","article-title":"Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3","volume":"44","author":"Kowalczyk","year":"2014","journal-title":"Eur J Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00262-015-1791-4","article-title":"IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells","volume":"65","author":"Ohno","year":"2016","journal-title":"Cancer Immunol. IO"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.3844","article-title":"IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation1","volume":"173","author":"Park","year":"2004","journal-title":"J Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1634\/theoncologist.2007-0127","article-title":"Peripheral blood dendritic cell subsets from patients with monoclonal gammopathies show an abnormal distribution and are functionally impaired","volume":"13","author":"Mart\u00edn-Ayuso","year":"2008","journal-title":"Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623975","article-title":"Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing","volume":"126","author":"Leone","year":"2015","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/14653240410006004","article-title":"Impaired circulating myeloid DCs from myeloma patients","volume":"6","author":"Do","year":"2004","journal-title":"Cytotherapy"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001212","article-title":"Immune evasion by yersinia enterocolitica: Differential targeting of dendritic cell subpopulations In Vivo","volume":"6","author":"Autenrieth","year":"2010","journal-title":"PLoS Pathog"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2020.02.015","article-title":"Dendritic cell development in infection","volume":"121","author":"Bieber","year":"2020","journal-title":"Mol Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00728-2","article-title":"Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection","volume":"18","author":"P\u00e9rez-G\u00f3mez","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101855","article-title":"Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells","volume":"189","author":"Sawant","year":"2012","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-1167","article-title":"Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity","volume":"68","author":"Huarte","year":"2008","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-22-1046","article-title":"Depletion of conventional type-1 dendritic cells in established tumors suppresses immunotherapy efficacy","volume":"82","author":"Teijeira","year":"2022","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-0352","article-title":"Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy","volume":"30","author":"Yang","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04984.x","article-title":"Either interleukin-12 or interferon-\u03b3 can correct the dendritic cell defect induced by transforming growth factor \u03b21 in patients with myeloma","volume":"125","author":"Brown","year":"2004","journal-title":"Br J Hematol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-\u03b21 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2022.101106","article-title":"Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential","volume":"88","author":"Smyth","year":"2022","journal-title":"Mol Asp Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15800","article-title":"Distinct mechanisms of dysfunctional antigen-presenting DCs and monocytes by single-cell sequencing in multiple myeloma","volume":"114","author":"Jiang","year":"2023","journal-title":"Cancer Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nri.2016.116","article-title":"Dendritic cell migration in health and disease","volume":"17","author":"Worbs","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1038\/s41598-018-23943-w","article-title":"Compromised functionality of monocyte-derived dendritic cells in multiple myeloma patients may limit their use in cancer immunotherapy","volume":"8","author":"Shinde","year":"2018","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3 + regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050463","article-title":"Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011353","article-title":"Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients","volume":"108","author":"Banerjee","year":"2006","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2016.12.008","article-title":"Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4","volume":"213","author":"Chen","year":"2017","journal-title":"Pathol - Res Pract"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1444821","article-title":"Type I-conventional dendritic cells support the progression of multiple myeloma in the bone marrow","volume":"15","author":"Suzuki","year":"2024","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.5723","article-title":"Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure","volume":"13","author":"Lambert","year":"2017","journal-title":"Oncol Lett"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.02.008","article-title":"Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease","volume":"83","author":"Wolf","year":"2014","journal-title":"Eur J Radiol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2019180096","article-title":"Whole-body imaging of multiple myeloma: Diagnostic criteria","volume":"39","author":"Ormond Filho","year":"2019","journal-title":"RadioGraphics"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(97)10133-2","article-title":"Myeloma bone disease","volume":"34","author":"Mundy","year":"1998","journal-title":"Eur J Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070314","article-title":"Dendritic cells at the osteo-immune interface: Implications for inflammation-induced bone loss1*","volume":"22","author":"Alnaeeli","year":"2009","journal-title":"J Bone Mineral Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211920","article-title":"Dominant role of CD47\u2013thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: Implications for bone disease","volume":"114","author":"Kukreja","year":"2009","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12333","article-title":"Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation","volume":"161","author":"Tucci","year":"2013","journal-title":"Br J Hematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/jci60920","article-title":"Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function","volume":"122","author":"Charles","year":"2012","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.11005\/jbm.2023.30.2.127","article-title":"Origin of osteoclasts: Osteoclast precursor cells","volume":"30","author":"Tsai","year":"2023","journal-title":"J Bone Metab"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0041","article-title":"Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment","volume":"104","author":"Rivollier","year":"2004","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1172\/jci5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-208249","article-title":"Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments","volume":"114","author":"Kryczek","year":"2009","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1333993","article-title":"Research progress of targeted therapy regulating Th17\/Treg balance in bone immune diseases","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/lymphatics3010002","article-title":"Advancements in multiple myeloma therapies: A comprehensive review by disease stage","volume":"3","author":"Khatib","year":"2025","journal-title":"Lymphatics"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: Mission accomplished","volume":"143","author":"Rasche","year":"2024","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41408-022-00719-0","article-title":"Smoldering multiple myeloma current treatment algorithms","volume":"12","author":"Rajkumar","year":"2022","journal-title":"Blood Cancer J"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2409029","article-title":"Daratumumab or active monitoring for high-risk smoldering multiple myeloma","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-024-01353-5","article-title":"Cytokine-overexpressing dendritic cells for cancer immunotherapy","volume":"56","author":"Han","year":"2024","journal-title":"Exp Mol Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1399","article-title":"Dendritic cell\u2013based immunotherapy: State of the art and beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.21873\/anticanres.17196","article-title":"Personalized dendritic-cell-based vaccines targeting cancer neoantigens","volume":"44","author":"Kamigaki","year":"2024","journal-title":"Anticancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: Impact on myeloid-derived suppressor cells","volume":"13","author":"S\u00e1nchez-Le\u00f3n","year":"2022","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/vaccines8040706","article-title":"DC-based vaccines for cancer immunotherapy","volume":"8","author":"Fu","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2019.12.017","article-title":"Manufacturing dendritic cells for immunotherapy: Monocyte enrichment","volume":"16","author":"Hopewell","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B96","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12967-015-0528-7","article-title":"Different maturation cocktails provide dendritic cells with different chemoattractive properties","volume":"13","author":"Massa","year":"2015","journal-title":"J Trans Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2096363","article-title":"Trial watch: Dendritic cell (DC)-based immunotherapy for cancer","volume":"11","author":"Laureano","year":"2022","journal-title":"OncoImmunology"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.3390\/cells12172147","article-title":"Dendritic cell vaccines: A shift from conventional approach to new generations","volume":"12","author":"Lee","year":"2023","journal-title":"Cells"},{"key":"B99","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms23020904","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: Challenges, opportunities, and future directions","volume":"23","author":"Verheye","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2012_057","article-title":"Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma\u2013phase II study results","volume":"59","author":"Zahradova","year":"2012","journal-title":"Neoplasma"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000182","article-title":"Ex vivo induction of multiple myeloma-specific immune responses by monocyte-derived dendritic cells following stimulation by whole-tumor antigen of autologous myeloma cells","volume":"40","author":"Vasileiou","year":"2017","journal-title":"J Immunother"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01079","article-title":"Autologous hematopoietic stem cells are a preferred source to generate dendritic cells for immunotherapy in multiple myeloma patients","volume":"10","author":"Shinde","year":"2019","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1199","article-title":"Mature dendritic cells enriched in immunoregulatory molecules (mregDCs): A novel population in the tumor microenvironment and immunotherapy target","volume":"13","author":"Li","year":"2023","journal-title":"Clin Trans Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nm0598-594","article-title":"Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell derived exosomes","volume":"4","author":"Zitvogel","year":"1998","journal-title":"Nat Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clim.2015.03.021","article-title":"Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases","volume":"160","author":"Tran","year":"2015","journal-title":"Clin Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2022.2109486","article-title":"Dendritic cell-based vaccines against cancer: Challenges, advances and future opportunities","volume":"51","author":"Fu","year":"2022","journal-title":"Immunol Investig"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/s41435-024-00294-3","article-title":"Next-generation DC vaccines with an immunogenic trajectory against cancer: Therapeutic opportunities vs. resistance mechanisms","author":"Sprooten","year":"2024","journal-title":"Genes Immun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109592","article-title":"A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy","volume":"114","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120466","article-title":"Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside","volume":"297","author":"Ghorbaninezhad","year":"2022","journal-title":"Life Sci"},{"key":"B111","doi-asserted-by":"publisher","first-page":"188763","DOI":"10.1016\/j.bbcan.2022.188763","article-title":"The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants","author":"Ding","year":"1877","journal-title":"Biochim Biophys Acta (BBA) - Rev Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02654-0","article-title":"Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma","volume":"70","author":"Chu","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B113","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2010-04-277137","article-title":"Vaccination with dendritic cell\/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma","volume":"117","author":"Rosenblatt","year":"2011","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ajh.21560","article-title":"Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival","volume":"84","author":"Lacy","year":"2009","journal-title":"Am J Hematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: Optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1575509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T01:24:24Z","timestamp":1744853064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1575509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":115,"alternative-id":["10.3389\/fimmu.2025.1575509"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1575509","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"article-number":"1575509"}}